drugset
drugset / Trial / NCT05990998

A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study

NCT05990998 ↗

Phase 1/2 Completed 38 enrolled First Affiliated Hospital of Fujian Medical University
NaSingle-groupOpen-labelDiagnostic

Summary

Both fibroblast activation protein (FAP)-targeted imaging and somatostatin receptors (SSTR)-targeted imaging were the promising imaging modalities for the diagnosis of primary and metastatic nasopharyngeal carcinoma (NPC). This prospective study is going to investigate to compare the diagnostic efficacy of 68Ga-FAPI and 68Ga-DOTATATE in detecting primary and metastatic NPC lesions, thereby obtaining a more accurate examination method of NPC.

Timeline

Start
2022-11-20
Primary completion
2023-08-31
Completion
2023-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-DOTATATE Diagnostic / imaging agent 74 mbq Intravenous
Subject 68Ga-DOTATATE Diagnostic / imaging agent 148 mbq Intravenous
Subject FAPI GA-68 Diagnostic / imaging agent 74 mbq Intravenous
Subject FAPI GA-68 Diagnostic / imaging agent 148 mbq Intravenous

Indications

No indication recorded.